MarrowXpress System used for isolation and retrieval of bone marrow-derived adult stem cells

Celling Technologies collaborated with innovative cell processing expert, ThermoGenesis Corp., to deliver the most sophisticated point of care cell separation device on the market. The innovative MarrowXpress(TM) (MXP(TM)) System defines a new standard for isolation and retrieval of bone marrow-derived adult stem cells. The MXP System consistently yields high (> 90%) mononuclear cell recovery and allows for easy data tracking through the proprietary data management software.

"The regenerative medicine technologies under development today represent new and exciting opportunities to cure disease and restore patients to full and healthy function. Celling Technologies is committed to the development and delivery of the most advanced regenerative products to achieve these ambitious clinical results. We partnered with ThermoGenesis because they are experts in cell separation and storage. Together, over the next several years, we will be advancing the clinical applications of adult stem cells through performance and outcome-based clinical studies," says Dr. Jim Poser, Executive Vice President of Regenerative Medicine for Celling.

Celling is working with Dr. Robert Johnson of Neurosurgical Associates of San Antonio, who has pioneered stem cell therapy in spine surgery. Dr. Johnson believes that current technologies on the market have only begun scratching the surface on cell isolation capabilities.

"I believe the mono-nucleated cell recoveries are a critical component to bone healing and I want to know the dose I am delivering back to my patient has the highest yield of cells I can concentrate. The MXP device takes human error out of the process by using technology to drive better results. At the current stage of stem cell therapy, I believe the more cell recovery the better and I want to offer the best technology to get those results," said Dr. Johnson.

Dr. Johnson worked closely with the team from Celling and ThermoGenesis to evaluate the clinical applications of the MXP System and will continue working to further develop its capabilities. Celling believes the MXP system provides high yields of cell concentration, a closed system that minimizes the risk for contamination and data collection capabilities for clinical research and patient reporting.

Celling Technologies is currently developing stem cell therapy in general orthopedics, cardiovascular, plastic surgery and trauma. Close collaboration with key surgeons will help define the scope of opportunity for cell therapy. Celling's current objective for stem cell therapy is to define the standard of care through clinical performance and potentially lower healthcare costs by offering different means of preventative medicine.